Skip to main content

A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.

Publication ,  Journal Article
Thompson, EM; Ashley, DM; Ayasoufi, K; Norberg, P; Archer, G; Buckley, ED; Herndon, JE; Walter, A; Archambault, B; Flahiff, C; Jaggers, D ...
Published in: Nat Cancer
September 2025

The human cytomegalovirus (CMV) antigen pp65 is expressed in high-grade glioma (HGG) and medulloblastoma but not in the adjacent brain. This single-arm phase 1 trial ( NCT03299309 ) assessed the safety and immunogenicity of a peptide vaccine (PEP-CMV) targeting pp65 in individuals (3-35 years old) with recurrent HGG or medulloblastoma. Thirty-six individuals with HGG received PEP-CMV. The mean age was 22.75 ± 9.34 years. The primary outcome, percentage of unacceptable toxicity, was met. The maximum-grade adverse events (AE) related to PEP-CMV were 17 grade 1 AEs, 15 grade 2 AEs, 1 grade 3 AE (pyramidal tract syndrome) and 1 grade 4 AE (cerebral edema). As a secondary outcome, in 21 individuals with evaluable data, T cell reactivity, measured as change in baseline interferon-γ pp65 enzyme-linked immunospot assay reactivity, had an estimated increase of 46 spots (95% confidence interval (95% CI): 8, 194) after treatment with PEP-CMV. As exploratory endpoints, the median progression-free survival was 2.5 months (95% CI: 2.2, 3.2), and median overall survival was 6.5 months (95% CI: 4.6, 8.4). PEP-CMV is well tolerated and elicits an antigen-specific immune response in individuals with multiply recurrent HGG. Only two individuals with medulloblastoma were enrolled, showing one grade 3 encephalopathy possibly related to PEP-CMV, while neither had postvaccine immune assessments due to progression-free survival and overall survival less than 2 months.

Duke Scholars

Published In

Nat Cancer

DOI

EISSN

2662-1347

Publication Date

September 2025

Volume

6

Issue

9

Start / End Page

1559 / 1569

Location

England

Related Subject Headings

  • Young Adult
  • Viral Matrix Proteins
  • Vaccines, Subunit
  • Protein Subunit Vaccines
  • Phosphoproteins
  • Neoplasm Recurrence, Local
  • Medulloblastoma
  • Male
  • Humans
  • Glioma
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Thompson, E. M., Ashley, D. M., Ayasoufi, K., Norberg, P., Archer, G., Buckley, E. D., … Landi, D. (2025). A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial. Nat Cancer, 6(9), 1559–1569. https://doi.org/10.1038/s43018-025-00998-z
Thompson, Eric M., David M. Ashley, Katayoun Ayasoufi, Pamela Norberg, Gerald Archer, Evan D. Buckley, James E. Herndon, et al. “A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.Nat Cancer 6, no. 9 (September 2025): 1559–69. https://doi.org/10.1038/s43018-025-00998-z.
Thompson EM, Ashley DM, Ayasoufi K, Norberg P, Archer G, Buckley ED, et al. A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial. Nat Cancer. 2025 Sep;6(9):1559–69.
Thompson, Eric M., et al. “A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.Nat Cancer, vol. 6, no. 9, Sept. 2025, pp. 1559–69. Pubmed, doi:10.1038/s43018-025-00998-z.
Thompson EM, Ashley DM, Ayasoufi K, Norberg P, Archer G, Buckley ED, Herndon JE, Walter A, Archambault B, Flahiff C, Jaggers D, Gorski L, Sanchez LA, Congdon K, Hotchkiss K, Cook SL, Moelker E, Vlahovic G, Reap E, Schroeder K, Randazzo D, Desjardins A, Johnson MO, Peters K, Khasraw M, Friedman H, Mitchell DA, Sampson JH, Landi D. A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial. Nat Cancer. 2025 Sep;6(9):1559–1569.

Published In

Nat Cancer

DOI

EISSN

2662-1347

Publication Date

September 2025

Volume

6

Issue

9

Start / End Page

1559 / 1569

Location

England

Related Subject Headings

  • Young Adult
  • Viral Matrix Proteins
  • Vaccines, Subunit
  • Protein Subunit Vaccines
  • Phosphoproteins
  • Neoplasm Recurrence, Local
  • Medulloblastoma
  • Male
  • Humans
  • Glioma